About NKGen Biotech
NKGen Biotech is a publicly listed company based in Santa Ana (United States) founded in 2017 by Sangwoo Park. Cell therapies for cancer and neurodegenerative conditions are developed. NKGen Biotech has raised $11 million across 1 funding round. Its chief executive, as recorded, is Sangwoo Park. NKGen Biotech offers products and services including NK Cell Therapies and SNK Manufacturing. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is NKGen Biotech, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
NKGen Biotech was founded in 2017 and is headquartered in Santa Ana, United States. Natural killer cell therapies, including SNK01, are developed for solid tumors, breast cancer, lung cancer, and neurodegenerative disorders. These therapies are employed alone or in combination with other drugs within the biotechnology sector focused on oncology and neurology. Operations center on advancing cellular treatments for these medical areas.
- Headquarters Santa Ana, United States
- Founders Sangwoo Park
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nkgenbiotech.com
- Social LinkedIn X
- Legal Name Nkgen Biotech Inc.
- Net Profit-$44.29 M (USD)46.61as on Dec 31, 2024
- EBITDA-$25.65 M (USD)10.13as on Dec 31, 2024
- Total Equity Funding$11M (USD)
in 1 rounds
- Latest Funding Round$11M (USD), Seed
Dec 2019
Products & Services of NKGen Biotech
NKGen Biotech offers a comprehensive portfolio of products and services, including NK Cell Therapies and SNK Manufacturing.
Enhances immune response to target and eliminate diseased cells effectively.
Manufactures NK cell therapies for clinical trial applications.
Funding Insights of NKGen Biotech
NKGen Biotech has successfully raised a total of $11M through 1 strategic funding round. The most recent funding activity was a Seed round of $11 million completed in December 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11M
- Total Rounds 1
- Last Round Seed — $11M
- First Round $11M
(Dec 2019)
All 1 funding rounds of NKGen Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2019 | $11M | Seed | – | – | – |
People of NKGen Biotech
15 people are tracked at NKGen Biotech (9 in leadership, 4 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Sangwoo Park | Founder & CEO | Leadership |
Pierre Gagnon | COO | Leadership |
Ryan Park | VP, Finance & Accounting | Leadership |
Paul Song | CEO & Vice Chairman | Leadership |
Will de Groot | Chief Business Officer | Leadership |
Denise Chua | VP, Investor Relations & Corporate Communications | Leadership |
Yoonmi Kang | VP, Technical Operations | Leadership |
Irene Chang | VP, Human Resources | Leadership |
Paul Chang | VP, Development Operations | Leadership |
Craig Blackstone | Scientific Advisor, Neuro | Board & advisors |
Ming Guo | Scientific Advisor | Board & advisors |
Anthony T. Reder | Scientific Advisor, Neuro | Board & advisors |
Evren Alici | Scientific Advisor | Board & advisors |
Yong Man Kim | CSO & CIO | Team |
Maria Rosadel Dionisio | Senior Manager, Regulatory CMC | Team |
Complete people profiles for NKGen Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of NKGen Biotech
NKGen Biotech is a publicly listed company on the OTC with ticker symbol NKGN in USA, operating in the Finance sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 May 2021
- Listed onNYSE: GFORU
- Listed entityNKGen Biotech Inc.
- Exchange sectorFinance
- ISINUS65488A1016
- Share price$0.01 · 2026-10-09
- Market capitalisation$1.4M
- Volume (last session)5,185
Financials of NKGen Biotech
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | -$44.3M | -$25.6M | |
| 2023 | -$83.0M | -$28.5M | |
| 2022 | $77,000 | -$26.8M | -$23.1M |
| 2021 | -$990,640 | -$2.5M |
Detailed financial statements for NKGen Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of NKGen Biotech
3 dated milestones of NKGen Biotech across 4 years, from founding to its latest funding, stage changes and deals.
- Founded NKGen Biotech is founded.
- Funding First funding round of $11.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of NKGen Biotech
NKGen Biotech has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of NKGen Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NKGen Biotech
The website of NKGen Biotech (nkgenbiotech.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 5.8% vs previous month
Websites whose visitors overlap most with NKGen Biotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| realmidx.com | 100% | View details | |||
| amberstonebio.com | 93% | View details | |||
| invitrx.com | 88% | View details | |||
advan-bio.com | advan-bio.com | 86% | – | ||
| clearpointneuro.com | 85% | 12.3K | #1,849,021 | View details |
Top companies in Cell Therapy
3 companies that operate in the same segment as NKGen Biotech (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nkgen Biotech
Complete news archive for NKGen Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NKGen Biotech
NKGen Biotech was founded in 2017 and raised its 1st funding round 2 years after it was founded.
NKGen Biotech is headquartered in Santa Ana, United States. It is registered at Santa Ana, California, United States.
Sangwoo Park is the CEO of NKGen Biotech, as recorded in our data. They have also founded this company.
NKGen Biotech is a funded company, having raised a total of $11M across 1 funding round to date. The company's 1st funding round was a Seed of $11M, raised on Dec 2019.
NKGen Biotech was founded in 2017 and is headquartered in Santa Ana, United States. Natural killer cell therapies, including SNK01, are developed for solid tumors, breast cancer, lung cancer, and neurodegenerative disorders. These therapies are employed alone or in combination with other drugs within the biotechnology sector focused on oncology and neurology. Operations center on advancing cellular treatments for these medical areas.
NKGen Biotech offers NK Cell Therapies and SNK Manufacturing.
Yes, NKGen Biotech is publicly traded on OTC under the ticker symbol NKGN.
NKGen Biotech operates through Nkgen Biotech, Inc..